Abstract:OBJECTIVE:To explore the molecular biological mechanism for tanshinone II A reversing left ventricular hypertrophy, it would be studying the effect of tashinone on the endothelial nitric oxide synthase (eNOS) and protein kinase C (PKC) in the hypertrophic cadiocyte of rats suffered abdominal aorta constriction.METHOD:SD rats were operated with abdominal aorta constriction and 8 rats were done with sham surgery. After 4 weeks, all rats were divided into 4 groups: myocardial hypertrophy group, low dose tanshinone II A group (10 mg x kg(-1) x d(-1)), high dose tanshinone II A group (20 mg x kg(-1) x d(-1)) and valsartan group (10 mg x kg(-1) d(-1) intragastric administration). 8 weeks later, the rats were used to measure the left ventricular mass index (LVMI) with the tissue of left ventricle and myocardial fiber dimension (MFD) by pathological section and HE stain, to detect the nitric oxide content by nitrate reductase, to detect the genic expression of eNOS by RT-PCR and to detect the activity of protein kinase C (PKC) by Western blotting.RESULT:1) The blood pressure in group myocardial hypertrophy [(186 +/- 13) mmHg] and tansginone II A [low and high dose (188 +/- 11,187 +/- 14) mmHg] was obviously higher than that in group sham surgery and valsartan group [vs (117 +/- 8, 136 +/- 15) mmHg, P < 0.01]. But there was no difference between group myocardial hypertrophy and group tanshinone II A (low and high dose). 2) The LVMI and MFD were obviously higher in group tanshinone II A low and high dose) and group valsartan than those in group sham surgery (P < 0.05), and lower than those in group myocardial hypertrophy (P < 0.01). 3) The NO level was obviously higher in group tanshinone II A (low and high dose) and group valsartan than that in group myocardial hypertrophy (12.78 +/- 1.66, 11.95 +/- 1.39, 12.26 +/- 2.08 vs 5.83 +/- 1.06) micromol x L(-1), (P < 0.01 ), and lower than that in group sham surgery (vs 19.35 +/- 1.47) micromol x L(-1), (P < 0.05). 4) The expressive level of eNOS mRNA and protein in myocardial hypertrophy group was less than that in other groups (P < 0.01). And valsartan group was less than tanshinone II A groups and sham surgery group (P < 0.05), but there were no difference among the two tanshinone II A groups and sham surgery group. 5) The level of PKC protein in group myocardial hypertrophy was obviously higher than that in all the other groups (1.291 +/- 0.117 vs 0.563 +/- 0.094, 0.605 +/- 0.051, 0.519 +/- 0.062, 0.827 +/- 0.086, P < 0.01), and the level in group valsartan was higher than that in group sham operation and group tanshinone II A (low and high dose).CONCLUSION:NO/NOS system in local myocardium has close relationship with the pathological process for myocardial hypertrophy. Tanshinone II A can produce the pharmacological action to reverse myocardial hypertrophy by inhibiting the activity of PKC and promoting the genic expression of eNOS in local myocardium and the production of endogenous NO.

Nardosinone Protects H9c2 Cardiac Cells from Angiotensin Ii-Induced Hypertrophy

Naringenin Protects Against Septic Cardiomyocyte Injury Via PI3K- AKT Signaling Pathway

The Role of Inos-Derived NO in the Antihypertrophic Actions of B-type Natriuretic Peptide in Neonatal Rat Cardiomyocytes

Naringenin Alleviates Angiotensin Ⅱ Induced Neonatal Rat Ventricular Cardiomyocytes Hypertrophy

[Molecular Mechanism of Nitric Oxide in Preventing Cardiomyocytes from Hypertrophic Response Induced by Angiotensin II].

Tanshinone Iia Protects Against Cardiac Hypertrophy Via Inhibiting Calcineurin/Nfatc3 Pathway

Naringenin Attenuates Pressure Overload-Induced Cardiac Hypertrophy.

Nobiletin, a Polymethoxy Flavonoid, Protects Against Cardiac Hypertrophy Induced by Pressure-Overload via Inhibition of NAPDH Oxidases and Endoplasmic Reticulum Stress.

Effects of tanshinone II A on preventing angiotensin II-induced hypertrophy of cardiomyocytes

Icariin Attenuates Angiotensin II-induced Hypertrophy and Apoptosis in H9c2 Cardiomyocytes by Inhibiting Reactive Oxygen Species-Dependent JNK and P38 Pathways.

Naringenin Inhibits N-G-nitro-L-arginine Methyl Ester-Induced Hypertensive Left Ventricular Hypertrophy by Decreasing Angiotensin-Converting Enzyme 1 Expression

Angiotensin-(1-7) Attenuates Angiotensin II-induced Cardiac Hypertrophy Via a Sirt3-dependent Mechanism.

Tanshinone IIA Prevents Cardiac Remodeling Through Attenuating NAD (P)H Oxidase-Derived Reactive Oxygen Species Production in Hypertensive Rats.

Naringenin Attenuates Isoprenaline-Induced Cardiac Hypertrophy by Suppressing Oxidative Stress through the AMPK/NOX2/MAPK Signaling Pathway

Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2/HO-1 Signaling Pathway

Mangiferin Protects against Angiotensin-II-Enhanced Hypertrophic Markers and Apoptosis in H9c2 Cardiomyocytes

Effect of Angiotensin II Receptor 1 Antisense Oligodoexynucleotides on Physiological and Pathophysiological Growth of Cardiomyocytes.

Notoginsenoside R1 attenuates ischemic heart failure by modulating MDM2/β arrestin2-mediated β2-adrenergic receptor ubiquitination

[Effect of Tashinone on Nitric Oxide Synthase in Hypertrophic Cardiomyocyte of Rats Suffered Abdominal Aorta Constriction].

Sodium Ferulate Inhibits Rat Cardiomyocyte Hypertrophy Induced by Angiotensin II Through Enhancement of Endothelial Nitric Oxide Synthase/Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway

Sulforaphane protects H9c2 cardiomyocytes from angiotensin II-induced hypertrophy